Group One Trading’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,700
Closed -$5.37K 7498
2024
Q4
$5.37K Buy
+2,700
New +$7.07K ﹤0.01% 6388
2024
Q2
Sell
-9,500
Closed -$42.7K 6622
2024
Q1
$42.7K Buy
+9,500
New +$35K ﹤0.01% 4842
2023
Q3
Sell
-400
Closed -$860 7564
2023
Q2
$860 Buy
+400
New +$899 ﹤0.01% 7284
2022
Q1
Sell
-2,500
Closed -$51K 7951
2021
Q4
$51K Buy
+2,500
New +$60.3K ﹤0.01% 6318
2021
Q3
Sell
-100
Closed -$2K 8097
2021
Q2
$2K Buy
+100
New +$2.32K ﹤0.01% 7914

Other funds holding ADCT

Group One Trading's ADCT Position: Q2 2026 in Review

Group One Trading held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 100 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #7403.

Group One Trading first reported a position in ADCT in Q4 2020 and has held it in 14 quarters since. The position peaked at $21.5K in Q1 2024. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Group One Trading held 100 shares of ADC Therapeutics worth $107 as of Q2 2026.
  • Group One Trading left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7403 holding.
  • Group One Trading first reported a position in ADC Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • Group One Trading's ADC Therapeutics position peaked at $21.5K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.